↓ Skip to main content

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Overview of attention for article published in Clinical Cancer Research, January 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

patent
8 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
295 Dimensions

Readers on

mendeley
103 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Published in
Clinical Cancer Research, January 2009
DOI 10.1158/1078-0432.ccr-08-0596
Pubmed ID
Authors

Alain C. Mita, Louis J. Denis, Eric K. Rowinsky, Johann S. DeBono, Andrew D. Goetz, Leonel Ochoa, Bahram Forouzesh, Muralidhar Beeram, Amita Patnaik, Kathleen Molpus, Dorothée Semiond, Michèle Besenval, Anthony W. Tolcher

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 103 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 2 2%
United Kingdom 1 <1%
Unknown 100 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 24 23%
Student > Master 13 13%
Student > Ph. D. Student 11 11%
Student > Bachelor 11 11%
Other 9 9%
Other 17 17%
Unknown 18 17%
Readers by discipline Count As %
Medicine and Dentistry 36 35%
Agricultural and Biological Sciences 13 13%
Biochemistry, Genetics and Molecular Biology 11 11%
Chemistry 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 8 8%
Unknown 25 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2024.
All research outputs
#2,027,931
of 23,053,169 outputs
Outputs from Clinical Cancer Research
#1,641
of 12,659 outputs
Outputs of similar age
#10,279
of 186,336 outputs
Outputs of similar age from Clinical Cancer Research
#11
of 184 outputs
Altmetric has tracked 23,053,169 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,659 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 184 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.